Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALPESH DESAI

Allopathic & Osteopathic Physicians Dermatology

NPI
1386696904
CMS profile
198410
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$93,089.25

110 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Scientific Affairs, LLC $65,003.37 37
AbbVie Inc. $20,370.20 24
NOVARTIS PHARMACEUTICALS CORPORATION $5,867.11 27
Janssen Biotech, Inc. $1,612.20 9
Regeneron Healthcare Solutions, Inc. $143.01 6
GENZYME CORPORATION $64.14 5
Allergan, Inc. $29.22 2

Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALPESH DESAI

NPI 1386696904 · CMS profile ID 198410

Allopathic & Osteopathic Physicians / Dermatology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386696904?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALPESH DESAI, NPI 1386696904, CMS profile ID 198410. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386696904?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ALPESH DESAI, NPI 1386696904, CMS profile ID 198410. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386696904?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ALPESH DESAI, NPI 1386696904, CMS profile ID 198410, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1386696904?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

110 matching records · $93,089.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 110 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 110.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $80.0008/25/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809572529 CMS
Regeneron Healthcare Solutions, Inc. $9.1108/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809572531 CMS
AbbVie Inc. $3,500.0008/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794351307 CMS
AbbVie Inc. $28.1208/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794351305 CMS
AbbVie Inc. $166.6808/18/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794351301 CMS
AbbVie Inc. $101.3308/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794351303 CMS
AbbVie Inc. $2,500.0008/06/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794351299 CMS
AbbVie Inc. $26.4907/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794351297 CMS
Janssen Scientific Affairs, LLC $938.0007/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788182619 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $2,100.0007/17/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814965323 CMS
Janssen Biotech, Inc. $5.4007/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788182601 CMS
Janssen Scientific Affairs, LLC $1,250.0007/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788182615 CMS
Janssen Scientific Affairs, LLC $1,250.0007/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788182617 CMS
Janssen Scientific Affairs, LLC $1,250.0006/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788182613 CMS
Janssen Scientific Affairs, LLC $1,250.0006/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788182611 CMS
Allergan, Inc. $14.8306/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792751525 CMS
Janssen Scientific Affairs, LLC $1,250.0006/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788182609 CMS
Janssen Biotech, Inc. $8.6606/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788182587 CMS
AbbVie Inc. $15.1705/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794351295 CMS
Regeneron Healthcare Solutions, Inc. $20.5805/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809572527 CMS
AbbVie Inc. $2,500.0005/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794351293 CMS
Janssen Scientific Affairs, LLC $1,250.0005/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788182605 CMS
AbbVie Inc. $19.3705/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794351291 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $9.6205/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814965453 CMS
Janssen Scientific Affairs, LLC $1,250.0005/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788182607 CMS
Janssen Biotech, Inc. $4.7305/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788182599 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $15.6605/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814965449 CMS
AbbVie Inc. $7.4604/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794351289 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $10.7404/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814965443 CMS
GENZYME CORPORATION $17.9904/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843704257 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $9.8404/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814965439 CMS
Janssen Biotech, Inc. $10.1704/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788182597 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $11.7204/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814965433 CMS
Janssen Scientific Affairs, LLC $938.0004/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788182603 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $13.8304/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814965333 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $12.5604/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814965427 CMS
Janssen Biotech, Inc. $1,562.5003/30/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788182585 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $17.9403/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814965421 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $11.7103/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814965417 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $15.0903/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814965411 CMS
Janssen Biotech, Inc. $3.2503/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788182591 CMS
Janssen Biotech, Inc. $4.7303/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788182593 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $12.4003/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814965399 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $12.9003/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814965405 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $12.5203/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814965395 CMS
AbbVie Inc. $1,500.0003/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794351287 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $14.6002/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814965329 CMS
AbbVie Inc. $1,000.0002/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794351285 CMS
AbbVie Inc. $6.9602/13/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794351283 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $12.1402/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814965389 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $93,588.68 121
PY2020 $61,509.47 81
PY2021 $93,089.25 110
PY2022 $156,991.04 217
PY2023 $188,926.14 275
PY2024 $743,913.99 141
PY2025 $230,236.36 149

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $89,049.96 30
PY2024 Principal investigator $463,944.58 81
PY2023 Principal investigator $316,896.64 75
PY2022 Principal investigator $111,388.52 26
PY2021 Principal investigator $154,421.75 12
PY2020 Principal investigator $12,577.73 4
PY2019 Principal investigator $8,082.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $8,133.00 11/25/2025 Non-covered Recipient Entity
Alpesh D Desai DO
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228817494
Principal investigator 1 PFIZER INC. $1,279.53 11/04/2025 Non-covered Recipient Entity
Dorisca Research Consulting LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228817498
Principal investigator 1 Janssen Research & Development, LLC $2,032.20 10/23/2025 Non-covered Recipient Entity
Alpesh D. Desai, D.O., P.A.
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175282877
Principal investigator 1 PFIZER INC. $468.45 10/09/2025 Non-covered Recipient Entity
Dorisca Research Consulting LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228825608
Principal investigator 1 PFIZER INC. $3,823.00 09/03/2025 Non-covered Recipient Entity
Dorisca Research Consulting LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228836873
Principal investigator 1 PFIZER INC. $1,368.63 08/05/2025 Non-covered Recipient Entity
Dorisca Research Consulting LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228841986
Principal investigator 1 Janssen Research & Development, LLC $1,016.10 07/31/2025 Non-covered Recipient Entity
Alpesh D. Desai, D.O., P.A.
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175282284
Principal investigator 1 Janssen Research & Development, LLC $1,016.10 07/31/2025 Non-covered Recipient Entity
Alpesh D. Desai, D.O., P.A.
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175282763
Principal investigator 1 PFIZER INC. $2,299.86 06/26/2025 Non-covered Recipient Entity
Dorisca Research Consulting LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228851017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 06/23/2025 Non-covered Recipient Entity
DORISCA RESEARCH CONSULTING LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210216
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 06/23/2025 Non-covered Recipient Entity
DORISCA RESEARCH CONSULTING LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210218
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 06/23/2025 Non-covered Recipient Entity
DORISCA RESEARCH CONSULTING LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210220
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $820.00 06/23/2025 Non-covered Recipient Entity
DORISCA RESEARCH CONSULTING LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210268
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 06/23/2025 Non-covered Recipient Entity
DORISCA RESEARCH CONSULTING LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210310
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 06/23/2025 Non-covered Recipient Entity
DORISCA RESEARCH CONSULTING LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210312
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 06/23/2025 Non-covered Recipient Entity
DORISCA RESEARCH CONSULTING LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210314
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,900.00 06/23/2025 Non-covered Recipient Entity
DORISCA RESEARCH CONSULTING LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210328
Principal investigator 1 PFIZER INC. $4,005.18 05/06/2025 Non-covered Recipient Entity
Dorisca Research Consulting LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228855393
Principal investigator 1 PFIZER INC. $3,154.95 04/10/2025 Non-covered Recipient Entity
Dorisca Research Consulting Inc
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228860297
Principal investigator 1 PFIZER INC. $44.55 04/08/2025 Non-covered Recipient Entity
Dorisca Research Consulting LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228860306
Principal investigator 1 PFIZER INC. $44.55 03/22/2025 Non-covered Recipient Entity
Dorisca Research Consulting LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228862813
Principal investigator 1 SANOFI US SERVICES INC. $3,730.00 03/17/2025 Non-covered Recipient Entity
Dorisca Research Consulting Inc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226096793
Principal investigator 1 PFIZER INC. $1,242.00 03/14/2025 Non-covered Recipient Entity
Dorisca Research Consulting Inc
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228862842
Principal investigator 1 Novartis Pharmaceuticals Corporation $33.19 03/10/2025 Non-covered Recipient Entity
MDRI BAYLOR UNIVERSITY
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1190301455
Principal investigator 1 PFIZER INC. $37,176.12 03/04/2025 Non-covered Recipient Entity
Dorisca Research Consulting LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228863008
Principal investigator 1 PFIZER INC. $695.00 02/27/2025 Non-covered Recipient Entity
ALPESH D DESAI DO PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO No dispute reported 06/30/2026 1228854432
Principal investigator 1 PFIZER INC. $1,583.55 02/06/2025 Non-covered Recipient Entity
Dorisca Research Consulting Inc
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228836868
Principal investigator 1 SANOFI US SERVICES INC. $3,647.00 01/21/2025 Non-covered Recipient Entity
Dorisca Research Consulting Inc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226096787
Principal investigator 1 PFIZER INC. $1,279.80 01/09/2025 Non-covered Recipient Entity
PRINCIPAL INVESTIGATOR
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228715967
Principal investigator 1 PFIZER INC. $2,257.20 01/09/2025 Non-covered Recipient Entity
PRINCIPAL INVESTIGATOR
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228715969